0.01Open0.01Pre Close0 Volume318 Open Interest1.50Strike Price0.00Turnover2554.53%IV46.60%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier-1DDays to Expiry0.01Extrinsic Value100Contract SizeAmericanOptions Type0.0903Delta0.6168Gamma103.00Leverage Ratio-0.5670Theta0.0000Rho9.31Eff Leverage0.0000Vega
Gossamer Bio Stock Discussion
loading...
loading...
Gossamer Bio a new outperform at Oppenheimer on seralutinib for PAH
• Oppenheimer has initiated Gossamer Bio at outperform expressing optimism on seralutinib, its inhaled tyrosine kinase inhibitor for pulmonary arterial hypertension (PAH).
• The firm has a $9 price target (~984% upside based on June 24 close).
• Analyst Andreas Argyrides said that the candidate's safety and efficacy profile makes it "a preferred choice among severe PAH patients who are not ad...
No comment yet